AUTO4

News alerts, weekly reports and conference planners

Company:

Autolus

Drug class:

TRBC1-targeted CAR-T immunotherapy

‹

›

10ms

Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma (clinicaltrials.gov)

P1/2, N=20, Completed, Autolus Limited | Active, not recruiting --> Completed | N=200 --> 20 | Trial completion date: Oct 2026 --> Dec 2024 | Trial primary completion date: Oct 2026 --> Dec 2024

10 months ago

Trial completion • Enrollment change • Trial completion date • Trial primary completion date

cyclophosphamide • fludarabine IV • AUTO4

over1year

Phase I/II Study Evaluating AUTO4 in Patients with TRBC1 Positive T Cell Lymphoma (clinicaltrials.gov)

P1/2, N=200, Active, not recruiting, Autolus Limited | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Oct 2026 | Trial primary completion date: Jul 2023 --> Oct 2026

over 1 year ago

Enrollment closed • Trial completion date • Trial primary completion date • CAR T-Cell Therapy

cyclophosphamide • AUTO4

over3years

First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma (ASH 2022)

Patients received lymphodepletion with fludarabine (30mg/m2 for 4 days) and cyclophosphamide (500mg/m2 for 2 days) (Flu/Cy) prior to AUTO4 infusion... AUTO4 treatment was well tolerated with no DLT. Early responses are encouraging, although no CAR T cell expansion was seen in peripheral blood which may translate to responses that are not durable. To address this, optimisation of the AUTO4 manufacturing process has been performed, resulting in a product with a more naïve phenotype.

over 3 years ago

P1 data • CAR T-Cell Therapy • IO biomarker

TNFRSF8 (TNF Receptor Superfamily Member 8)

cyclophosphamide • fludarabine IV • AUTO2 • AUTO4